Thymosin Beta 4 Case Study

Following successful studies using TB-500 by researchers at Wayne State University School of Medicine to together with the Kresge Eye Institute in Detroit, Michigan, RegeneRx Biopharmaceuticals, Inc published the results of this study which showed that thymosin beta 4 was an active corneal wound healing and anti-inflammatory agent Thymosin beta 4 is a protein that naturally occurs in all cells except in erythrocytes. Despite this protein being a key monomeric actin-sequestering peptide within cells and with ability to depolymerize F-actin, studies are showing that it has several diverse cellular functions. In this particular study, the researchers investigated the multiple mechanisms of action associated with Thymosin beta 4 and the role it

The researchers had linked synthetic thymosin beta 4 to potential application in promoting mycordial cell survival during acute myocardial infarction. They administered intravenous synthetic thymosin beta 4 or placebo to four cohorts that were each comprised of 10 healthy subjects. The cohorts were administered with rising doses of 42, 140, 420, or 1260 mg. for safety purposes, the patients were administered with the same dose regimen daily for 14 days. The researchers then performed evaluations on safety, incidence of treatment-emergent adverse effects, and pharmacokinetic parameters. The observed adverse events were mild or moderate and infrequent. The researchers did not observe any dose limiting toxicities or serious adverse effects. The pharmacokinetic profile after the administration of a single dose indicated a dose proportional response and the half-life was shown to increase directly with the increasing dose. Intravenous administration of the synthetic tymosine beta 4 as a single dose or in multiple daily doses within the range of 42-1260 mg had favorable tolerance with no signs of dose limiting